First AD

Second AD

Treatment Selection in the Frontline Setting of Advanced Clear Cell RCC    

Please give an introduction of advanced clear cell RCC, including typical disease presentation and the role of systemic therapies in treatment. 

Please give a summary of the first-line treatment options for advanced clear cell RCC

How do you approach treatment selection (IO+IO vs. IO+TKI, etc.) in the frontline setting?

Are there any key patient characteristics that inform this decision?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Video Series

ASCO 2024: Updates in the Treatment of Advanced Renal Cell Carcinoma

Peer Exchange

Dr. Pedro Barata, MD, MSc, provides an overview of advanced clear cell renal cell carcinoma (RCC), discussing its typical presentation, the role of systemic therapies, and summarizing the first-line treatment options available for this condition. 